Skip to content
value.today

Kiora Pharmaceuticals, Inc.

KPRX
$8 Mmarket cap on Oct 30, 2026+94.8% since Jan 2024
Compare
World rank
#26,348
Revenue
—
For year ending December-2025
Net income
$-11 M
SEC filing
Employees
—

Kiora Pharmaceuticals, Inc. in brief

Kiora Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Encinitas, California, USA. Its market value was $8 M on 30 October 2026, which makes it the 26,348th largest listed company in the world and the 4,342nd largest in the USA on this site. Brian M. Strem is its chief executive. Its largest business segments by sales in 2024 were Reportable (100%). Its shares trade under the symbol KPRX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Kiora Pharmaceuticals, Inc.

We are developing KIO-301, with an initial focus on patients with later stages of vision loss due to retinitis pigmentosa. KIO-301 is a potential vision-restoring small molecule that acts as a “photoswitch” specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including RP. We completed a Phase 1b clinical trial in September 2023 and presented topline results in November 2023 at the American Academy of Ophthalmology Annual Meeting. The full data package triggered multiple discussions with various potential pharmaceutical partners. After assessing available options, in January 2024, we partnered with Théa Open Innovation, a sister company of Laboratories Théa. In October 2024, we received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 in patients with retinitis pigmentosa. The ABACUS-2 trial is a 36 patient, multicenter, double-masked, randomized, controlled, multiple dose study enrolling patients with ultra-low vision or no light perception regardless of their underlying gene mutation associated with retinitis pigmentosa. Enrollment in the ABACUS-2 trial is currently ongoing. As KIO-301 and its sister molecules are ion channel modulators, the potential to treat other neurological diseases exists. KIO-301 (formerly known as B-203) was acquired through the Bayon Therapeutics, Inc. transaction which closed October 21, 2021.

From the company's annual report filed with the US SEC: read the report

Kiora Pharmaceuticals, Inc. timeline

3 events, 2006–2024
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2021
  4. ✎
    Renamed Kiora Pharmaceuticals Inc
    Formerly Eyegate Pharmaceuticals Inc.
  5. 2024
  6. 💰
    Record revenue of $16 million
    FY2024, the highest of the 4 years on record.

Events of Kiora Pharmaceuticals, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$3 M$6 M$9 M$12 M2023202420252026

World rank over time

▲ up 7,187 places since 2022
2022-12-25: #33541#33,54120222023-07-30: #33499#33,49920232024-01-05: #32864#32,86420242026-03-08: #12981#12,98120262026-08-01: #22843#22,84320262026-10-30: #26354#26,3542026

Rank in USA: #5,847 (Dec 2022) · #5,654 (Jul 2023) · #4,656 (Jan 2024) · #2,417 (Mar 2026) · #4,033 (Aug 2026) · #4,345 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.5×
Free cash flow yield
-129.3%
Net margin
—
Operating margin
—
Return on equity
-67.2%
Liabilities / assets
33.5%
Net debt
$-1M
Revenue growth
+160100.0%
R&D / revenue
48.9%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $2M, net income $-11M$2MFY18Fiscal year ending Dec 2019: revenue $3M, net income $-7M$3MFY19Fiscal year ending Dec 2020: revenue $0M, net income $-7M$0MFY20Fiscal year ending Dec 2021: revenue —, net income $-14M—FY21Fiscal year ending Dec 2022: revenue —, net income $-14M—FY22Fiscal year ending Dec 2023: revenue —, net income $-13M—FY23Fiscal year ending Dec 2024: revenue $16M, net income $4M$16MFY24Fiscal year ending Dec 2025: revenue —, net income $-11M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-13M$-11M—
Dec 2024$16M—$5M$4M22.4%
Dec 2023——$-13M$-13M—
Dec 2022——$-12M$-14M—
Dec 2021——$-14M$-14M—
Dec 2020$0M-99.6%$-7M$-7M-68600.0%
Dec 2019$3M+63.0%—$-7M-263.9%
Dec 2018$2M—$-11M$-11M-655.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-10M$0M$-10M$-2.64—
Dec 2024$9M$0M$9M$0.87—
Dec 2023$-10M$0M$-10M$-24.25—
Dec 2022$-10M$0M$-10M$-18.55—
Dec 2021$-11M$0M$-11M$-57.12—
Dec 2020$-7M$0M$-7M$-1.49—
Dec 2019$-8M$0M$-8M$-2.23—
Dec 2018$-11M$0M$-11M$-4.57—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $0M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-7M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26Three months to Sep 2026: revenue $1M, net income $-2M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Kiora Pharmaceuticals, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-13 M
Net income
$-11 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$24 M
Total liabilities
$8 M
Total equity
$16 M

As of December-2025

Top 21 institutional investors in Kiora Pharmaceuticals, Inc.#

As of Sep 30, 2026
21 institutions held 1.1 M shares (about 25.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 23.7%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 21 largest institutional investors in Kiora Pharmaceuticals, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Perceptive Advisors LLC438,4710 (0.00%)9.91%$1 MNov 16, 2026
2Millennium Management LLC176,784+102,582 (+138.25%)4.00%$0 MNov 16, 2026
3ADAR1 Capital Management, LLC167,9410 (0.00%)3.80%$0 MNov 16, 2026
4Citadel Advisors LLC86,739-29,272 (-25.23%)1.96%$0 MNov 16, 2026
5Geode Capital Management, LLC46,083+19,366 (+72.49%)1.04%$0 MNov 6, 2026
6Two Sigma Investments, LP39,944-48,848 (-55.01%)0.90%$0 MNov 16, 2026
7Renaissance Technologies LLC37,200+7,376 (+24.73%)0.84%$0 MNov 12, 2026
8Vanguard Capital Management LLC21,974+2,113 (+10.64%)0.50%$0 MNov 13, 2026
9Vanguard Fiduciary Trust Co17,730+4,700 (+36.07%)0.40%$0 MNov 13, 2026
10HRT Financial LP16,873-41,739 (-71.21%)0.38%$0 MNov 13, 2026
11XTX Topco Ltd16,396New0.37%$0 MNov 16, 2026
12Dimensional Fund Advisors LP16,055+3,917 (+32.27%)0.36%$0 MNov 4, 2026
13LPL Financial LLC12,5000 (0.00%)0.28%$0 MNov 6, 2026
14Northern Trust Corp11,7670 (0.00%)0.27%$0 MNov 16, 2026
15Caitong International Asset Management Co., Ltd1,624-189 (-10.42%)0.04%$0 MOct 29, 2026
16Tower Research Capital LLC (TRC)774-63 (-7.53%)0.02%$0 MNov 16, 2026
17SBI Securities Co., Ltd.2560 (0.00%)0.01%$0 MOct 22, 2026
18Pinnacle Financial Group, Inc.250—0.01%$0 MNov 16, 2026
19BlackRock, Inc.580 (0.00%)0.00%$0 MNov 13, 2026
20Activest Wealth Management20 (0.00%)0.00%$0 MOct 15, 2026
21Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Kiora Pharmaceuticals, Inc.#

10 funds hold shares worth $0 M (about 1.7% of the company). Since their previous reports 6 added shares and 0 sold, buying $0 M net.
Mutual funds holding Kiora Pharmaceuticals, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC35,972$0 M0.81%<0.01%+75%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.19,861$0 M0.45%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP3,923$0 M0.09%<0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC3,446$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP3,510$0 M0.08%<0.01%newJul 31, 2026
🇺🇸 Omni Small-Cap Value FundBridgeway Capital Management, LLC2,000$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP1,895$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP1,574$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP1,236$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC747$0 M0.02%<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Kiora Pharmaceuticals, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
26
since
$49 K$0Jun 2024: bought $49 K (4 trades), sold $0 (0 trades)Jun 24Aug 2024: bought $31 K (3 trades), sold $0 (0 trades)AugSep 2024: bought $15 K (2 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Kiora Pharmaceuticals, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Melissa ToscaCFOShares withheld for tax-911$2.660$2 K26,064Form 4
filed Brian M. StremPresident and CEO, DirectorShares withheld for tax-1,869$2.660$5 K58,823Form 4
filed Eric Joseph DanielsChief Development OfficerShares withheld for tax-929$1.950$2 K31,741Form 4
filed Brian M. StremPresident and CEO, DirectorShares withheld for tax-1,906$1.950$4 K60,692Form 4
filed Melissa ToscaCFOShares withheld for tax-929$1.950$2 K26,975Form 4
filed Eric Joseph DanielsChief Development OfficerGrant or award+6,533——32,670Form 4
filed Melissa ToscaCFOGrant or award+6,533——27,904Form 4
filed Brian M. StremPresident and CEO, DirectorGrant or award+16,733——62,598Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Kiora Pharmaceuticals, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
56,588
1.5% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-9 reverse split ; 1-for-40 reverse split ; 1-for-16.67 reverse split

Trading halts

  • 2025-06-04 14:09 UTC, code LUDP, resumed 14:14 UTC

Fails to deliver

  • : 461 shares at $1.76
  • : 5 shares at $2.69
  • : 58,308 shares at $2.16
  • : 2,222 shares at $2.07
  • : 546 shares at $2.10

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Kiora Pharmaceuticals, Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-129.3%Free cash flow is -129.3% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.64 vs 0.87Diluted EPS -2.64 in fiscal 2025 against 0.87 the year before (report's currency).
    • ✗Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$7 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-51.8%-51.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities6.0×Current ratio 5.99 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-0.5%Diluted shares down 0.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Kiora Pharmaceuticals, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Kiora Pharmaceuticals, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0160—00.02.71.70.40.7
Research and development117.84.03.45.43.65.48.1108.4
General and administrative5.75.54.78.35.34.74.44.44.65.6
Operating expenses1312131214r6.9r9.8121514
Operating income−134.5−13−12−14r−6.9r—−11——
Interest and finance income0.91.30.20.10.00.00.10.10.00.0
Interest expense and finance costs0.00.00.00.00.00.00.00.00.00.0
Other non-operating income (expense)0.71.10.2−1.40.3r0.0r0.10.1−0.00.0
Income before tax−125.7−12−14−14r−6.8r−7.0−11−15−13
Income tax−1.32.10.1−0.1−0.2r0.00.10.1−1.30
Net income including minority interests————————−13−13
Minority interests' share of net income————————−0.0−0.0r
Net income attributable to shareholders−113.6−13−14−14r−6.9r−7.1−11−13—
Earnings per share, basic-2.600.93-24.25r-18.55-57.12r-1.49r-2.23-4.57r-0.93-1.51
Earnings per share, diluted-2.640.87-24.25r-18.55-57.12r-1.49r-2.23-4.57r-0.93-1.51
Shares, weighted average (basic)4.23.90.5r0.70.2r4.6r————
Shares, weighted average (diluted)4.14.10.5r0.70.2r4.6r3.22.4r148.8
Balance sheet
Cash and cash equivalents8.73.82.56.07.91.23.88.07.83.6
Short-term investments8.4230———————
Receivables1.50.60———————
Other current assets1.12.00.20.30.60.40.50.50.60.5
Current assets22304.77.79.01.7r4.38.58.54.2
Property, plant and equipment0.10.00.00.10.10.00.00.00.10.0
Right-of-use (leased) assets0.30.10.10.10.20.1—0——
Goodwill———003.6r1.51.51.5—
Other intangible assets2.16.78.81111r9.74.14.23.9—
Total assets2436141920r15r1014149.7
Accounts payable1.10.40.21.00.20.40.20.10.71.4
Current liabilities3.66.01.63.31.62.0r1.43.9157.3
Long-term debt—————0.30———
Lease liabilities (non-current)0.20.00.100.10.00———
Non-current liabilities4.54.76.04.03.9r3.6r2.11.51.42.8
Total liabilities8.1117.67.35.6r5.6r3.55.31610
Retained earnings−154−143−147−134−121r−107r−100−93−92−79
Shareholders' equity16266.11115r9.7r6.68.9−1.9r−0.3
Total equity———————8.97.6r−0.3
Total liabilities and equity2436141920r15r1014149.7
Shares outstanding3.83.00.9r1.80.3r5.64.13.0r1710
Cash-flow statement
Depreciation and amortization0.00.00.10.00.00.00.10.00.00.0
Share-based compensation0.90.70.80.50.80.70.90.90.90.5
Cash from operating activities−10.08.6−9.6−10−11r−7.3−8.2−11−6.5−8.4
Capital expenditure−0.1−0.000−0.1−0.00−0.0−0.00
Intangible assets bought———————−0.30—
Acquisitions, net of cash acquired———0−0.1−0.1————
Cash from investing activities14−2300.0−0.2−0.20−0.3−0.00.2r
Debt issued————00.30———
Shares issued———5.418r5.01.9r1011r3.8
Cash from financing activities0.3156.08.618r5.03.911113.5
Exchange-rate effect on cash0.2−0.10.0−0.1−0.1−0.00.00.00.00.0
Change in cash4.91.3−3.6−1.96.7−2.6−4.20.24.2−4.7r
Report10-K10-K10-K10-K10-K10-K/A10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Kiora Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2024#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$16 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2024

Executive pay at Kiora Pharmaceuticals, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$972 K
Dr. Strem
Other top executives, average
$737 K
the CEO earned 1.3× this
$100 invested is now
—
Kiora Pharmaceuticals, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Strem$972 K$949 K$737 K—
2024Brian M. Strem$955 K$949 K$604 K—
2023Brian M. Strem$805 K$710 K$530 K—

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Kiora Pharmaceuticals, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 5 · Material agreement 4 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 11

Kiora Pharmaceuticals, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Kiora Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$5 MPrivate placement after listing$2 to $10 million3equity, optionsSEC
Feb 2024$15 MPrivate placement after listing$10 to $50 million13equity, optionsSEC
Aug 2021$11 MPrivate placement after listing$10 to $50 million14optionsSEC
Jan 2021$8 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Dec 2020$3 MPrivate placement after listing$2 to $10 million15equitySEC
Oct 2019$2 MPrivate placement after listingUnder $2 million1equity, optionsSEC
Jun 2016$4 MNo. 3$2 to $10 million2optionsSEC
Mar 2016$3 MIssued in a merger or acquisition$2 to $10 million32equitySEC
Dec 2010$4 MNo. 2$2 to $10 million9equitySEC
Dec 2009$11 MNo. 1$10 to $50 million20equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Kiora Pharmaceuticals, Inc. compares in Biotechnology

  • Market cap$8 M · higher than 8% of 726
  • Price / book0.5× · lower than 92% of 534
  • FCF yield-129.3% · higher than 6% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Kiora Pharmaceuticals, Inc.🇺🇸$8 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 19, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Kiora Pharmaceuticals, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Kiora Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Kiora Pharmaceuticals, Inc.? Suggest a correction